DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
| Revenue (TTM) | $13.84B |
| Gross Profit (TTM) | $4.49B |
| EBITDA | $2.79B |
| Operating Margin | 13.90% |
| Return on Equity | 81.00% |
| Return on Assets | 7.50% |
| Revenue/Share (TTM) | $194.22 |
| Book Value | $-11.41 |
| Price-to-Book | 91.65 |
| Price-to-Sales (TTM) | 1.07 |
| EV/Revenue | 1.997 |
| EV/EBITDA | 10.20 |
| Quarterly Earnings Growth (YoY) | 43.50% |
| Quarterly Revenue Growth (YoY) | 6.00% |
| Shares Outstanding | $64.19M |
| Float | $34.18M |
| % Insiders | 46.90% |
| % Institutions | 52.85% |
Volatility is currently contracting
DaVita HealthCare (DVA) reached $230.72 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.
ADM, CASY, DVA, CVS and BEN top a list of five non-AI S&P 500 stocks that surged more than 30% in 1H 2026 and still show momentum for 2H.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 2, 2026.
DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.
DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 30, 2026.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LYB, HRB and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 26th, 2026.
The latest trading day saw DaVita HealthCare (DVA) settling at $213.04, representing a +1% change from its previous close.
DVA is expanding kidney care through outpatient, home-centered and value-based programs while investing in AI-enabled scheduling.
